Call for Abstract

18th World Pharma Congress, will be organized around the theme “Challenges and Opportunities in Transforming the Pharma Industry”

Pharma Congress 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Pharma Congress 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Disease is the enemy of mankind, which affects part or all of organism.  Efforts to cure or improve the health condition against disease lead a remarkable improvement in pharmaceutical sciences. Pharmaceutical science is a wide range of combinations of scientific disciplines that contribute to the discovery and development of new drugs and therapies. Advancements in the branches of pharmaceutical sciences enhance the development of new reliable entities. Every aspect of the pharmaceutical science deals with the drug design, drug action, drug delivery, and drug disposition. According to the 2015 EU Industrial R&D Investment Scoreboard the pharmaceutical and biotechnology sector amounts to 18.2% of total business R&D expenditure worldwide. On the other side Europe drug manufacturing is 225000 €millions and exports were 361500 €millions. Europe spent 31,500 €millions on R&D in 2015 while US spent 47,061€millions.

Persistent innovative development is one of the eminent characters of pharmaceutical industry. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. The invention of new medicines and the improvement of existing drugs constitute the development firms in this industry. The occasional triumph of creating a novel therapy in an area with no prior treatments counts among the pharmaceutical industry’s most defining hallmarks. Germany is forecast to have highest increase in market value at € 11.4bn. Novartis is forecast to reduce its R&D spending, from $10.5bn in 2020 to only $9.2bn in 2022. Of the top 20, Celgene and Regeneron are forecast to grow their R&D expenses most rapidly, with R&D spend forecast to increase 11% per year until 2022. Overall, total R&D spends is expected to increase by 2.8% each year, reaching $182bn in 2022.

Pharmacotherapy deals in administering pharmaceutical drugs distinguishing from therapy using surgery, radiation, movement or other methods. Drug therapy complies patient care with various types of pharmaceutical drugs ensuring the safe, appropriate and economical use. North America is expected to account for more than half the therapeutic drug monitoring market share in 2015. It is the prime market for therapeutic drug monitoring. The market in Europe on the other hand is growing at a slower rate. Therapeutic Drug Monitoring Market’s worth is expected 2.55 Billion USD by 2020 globally.

Drug development involves enormous methods and development procedure to attain therapeutic effective level. Emerging new Formulation is a persistent process with utilisation of abundant knowledge of pharmaceutics. Considering all characteristics of substances used, and their behaviour towards formulations need more innovative approach of drug development. The global market value for drug development technologies market share was about 30% in 2015 valued at $18 billion followed by Bioanalytical Assays or instruments by about $14 billion. Innovative formulations are estimated to have contributed to 73%. To develop a new pharmaceutical formulation and to conduct clinical trials it cost at € 1,926 million in 2016.

To obtain a required therapeutic effect, type of formulation, technology and system for transporting drug are the important variables. Drug delivery technologies alter the drug release profiles, absorption, distribution, and elimination of product for the safety efficacy. Developing new avenues for drug delivery vehicles reported promising results. The practice of drug delivery has changed dramatically in the past few decades and even greater changes are anticipated in the near future. The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. This market is segmented based on route of administration, facility of use, and region.

Pharmaceutical formulations is extensive procedure involving  characterization of a drug's physical, chemical, and mechanical properties in order to choose what other ingredients (excipients) should be used in the preparation and resulting a safe and efficacy product. Modern pharmaceutical formulation is expanding its sector with technology and innovation to formulate eminent result oriented formulations. The global pharmaceutical excipients market is projected to reach USD 8.1 Billion in 2021 at a CAGR of 6.1% in the forecast period 2016 to 2021. The rising demand for new drug delivery systems, greater understanding of the functional benefits of excipients, growing pharmaceutical industry, and patent expiries of several blockbuster drugs are positively impacting the overall growth of the market.

Clinical trials are the clinical investigation of a drug that administered or dispensed to, or used involving one or more human subjects. Clinical trials are the major parameter for the approval of drug, as they mainly deals with the effectiveness and safety.  Clinical trials play a vital role in the development of new drug entity as it subjected to various phases for approval. Advancements in clinical trials enhance the drug development process by means of reducing time duration, sometimes the cost. The success rate of Phase II trials that proceed to Phase III, as of 2010, is 18%. The amount of money spent on Phase II/III trials in 2015 by Large Sponsors (R&D $500M+) was $465,725,000 on average, while Non-Large Sponsors (R&D <$500M) spent $13,352,000 on average. The entire process of a drug from lab to this point may take approximately 12 to 18 years (but not always), often costing over $1 billion.

Producing safe and effective formulation is the main goal for Pharmaceutical industry. Hence pharmaceutical industry has great concern towards impurities due to their adverse effects. The trends in pharmaceutical analysis focuses on the modern methods, technology  and tools for control of  related impurities, and faster analysis time, better separation  time and faster method development.

It deals with prevention of adverse drug reaction by collection, detection, assessment, monitoring.  It concerns with the identifying hazards associated with pharmaceutical formulation. The advancement associated with pharmacovigilance helps in producing the valid formulation by focussing on the collected data from patients and health care providers. U.S. pharmacovigilance market size was valued over USD 1 billion in 2015, and predicted to witness 10.7% CAGR from 2016 to 2024 to surpass USD 2.5 billion by 2024.

Regulatory Affairs has a very specific meaning within the healthcare industries. Its regulations are for systematic manufacturing and marketing of safe, efficacious and qualitative drugs. Improving new regulations and adapting to the technology regulatory affairs set new goals and challenges to the pharmaceutical formulation. The global regulatory affairs outsourcing market had a valuation of US$1.9 bn in 2014. The market is expected to expand at a substantial 11.5% CAGR from 2015 to 2023 and rise to a valuation of US$5.7 billion by 2023.

Pharmacy is a healthcare profession assisting individual in making the best use of medicine. Ethics are intended to state publicly the principles that form the fundamental basis of the roles and responsibilities of pharmacists. Spending on specialty drugs in 2012 in the United States was about $87 billion. Estimates suggest that it could quadruple by 2020, reaching about $400 billion

Pharmacists are becoming a more integral part of the health care team. Pharmacists do indeed dispense medicines, but first they check for any possible interactions with other medicines or medical conditions. They also instruct patients on how to take the medicines and will inform them about what to do if certain side effects arise. Pharmacy is the healthcare service science and expertise of preparing and dispensing drugs. Pharmacy Modern service includes more traditional and advanced compounding and dispensing medication healthcare. The biggest challenge facing pharmacy is continuing to communicate its role, deliver its value, and be reasonably reimbursed.

The Bureau of Labor Statistics projects a slower-than-average 3 percent employment growth for pharmacists by 2024, with the field adding 9,100 new jobs. Employment of pharmacists is expected to decline slightly in traditional retail settings because more people are having their prescriptions filled online or through mail order.

Pharmacokinetic studies are more important for therapeutic biologics. Identifying the key factors that govern absorption, distribution, metabolism, and excretion of biologics as therapeutic agents improved the opportunities for the scientists working in drug disposition research field. The European Union (EU) first approved a biologic in 2006, now there are more than 700 biosimilars approved or in the pipeline globally. Analysts expect the worldwide biosimilars market to reach $25 billion to $35 billion by 2020. Generics have larger share of total global medicine spend, increasing from 27 percent ($261 billion) in 2012 to 36 percent ($421 billion) by 2017.

GMP is Set of guidelines to manufacturers must meet to assure that the products are high quality and safe. GMP covers all aspects of production from the beginning to end of the manufacturing aspects. Introduced latest trends in GMP are risk- based approaches which are to encourage adoption of new technology by pharmaceutical industry.

Pharmaceutical industries are facing hurdles in adopting new technologies quickly.

Bio availability is the rate and extent of active drug absorbed and available for action. Assessment of “interchangeability” between the generic and the innovator product is carried out by a study of bioequivalence (BE). During formulation of new entities bio availability and bio equivalents are also prime parameters. Through the conduct of bioavailability and bioequivalence studies, Generic drug products results on average bioequivalence in drug absorption. The top 15 biopharmaceutical products each profits annual revenue of more than $2 billion, with some drugs generating sales of more than $10 billion a year. In 2015 the top NMEs include Pfizer’s Ibrance, J&J’s Darzalex and Gilead’s Genvoya with a cumulative value of $32bn of sales expected in 2020.

A pharmaceutical company is a commercial business licensed to research, develop, market and/or distribute drugs, most commonly in the context of healthcare. The winds of change are blowing through and, in fact, revolutionizing logistics in the global pharmaceutical industry. The prime contributing factors are raising costs, growing risks, changing consumer needs and tightening regulations, globally. Pharmaceuticals represented a US$300 bn-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is expected to surpass US$400 bn by 2018, with the ten largest pharmaceutical companies collectively commanding about a third of the market.

The life sciences sector’s growth correlates highly with countries’ general economic strength and health care spending levels, and both of these vary widely around the globe. In 2015 North America accounted for 48.7% of world pharmaceutical sales compared with 22.2% for Europe. According to IMS Health data, 58% of sales of new drug discovery made during the period 2010–2015 were on the US market, compared with 23% on the European market. Europe is ensuring competitive growth along with other countries.  By 2022, products currently in drug development will account for 17% of sales in Europe. Europe is expected to show a 3% CAGR 2016-22, mainly driven by the launch of new products currently in development. The penetration of biotech products is set to increase from a 24% market share in 2015 to 29% in 2022.